API maker begins circulation of second and final call money notice for partly paid-up rights shares, completing the last leg of its 2024 fundraising cycle
Union Health Minister says India’s healthcare model blends traditional wisdom with modern science, backed by Ayushman Bharat and Janaushadhi expansion
Cyble’s 2026 healthcare threat report flags a sharp rise in Asia-focused ransomware, with hospitals, elderly care, and diagnostic systems increasingly in cybercriminal crosshairs
The India FMCG business showed a sequential recovery and is expected to post high-single digit growth
The partnership aims to accelerate clinical trial timelines, boost data quality, and improve decision-making for sponsors worldwide
The new capital is expected to fund the company through 2029
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
The trial also demonstrated significant improvements across multiple secondary endpoints
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Subscribe To Our Newsletter & Stay Updated
